reated PPMS patients were predominantly female (52%) and 55 years old or younger (75%). 49% were treated with ocrelizumab; other DMTs were orals (19%), other monoclonal antibodies (15%), glatiramer acetate (10%), and interferons (7%). Ocrelizumab usage patterns did not differ by treating neurologist demographics. Ocrelizumab-treated versus other DMT-treated PPMS patients were more likely to be male (56% vs. 40%, p <0.05), but were not more likely to be younger (mean age 46.9 vs.  48.0 years, p =0.415). Proportion of patients aged 55 years or less was 73% in the ocrelizumab arm vs. 77% in the other DMT arm (p >0.05). Ocrelizumab use was greater among those neurologists who reported that age was not a constraint to use (66% vs. 30%, p <0.05); no correlation was found based upon neurologists’ self-reported attitude toward ocrelizumab being more effective in males.